stockrowTG Therapeutics, Inc.
TGTX Healthcare Biotechnology
TG Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $616.3 million, up 87.3% from fiscal 2024.
- Revenue
- +70.3%
- EPS
- −73.7%
- Free cash flow
- +427.1%
- Total debt
- +204.2%
Quarter to June 2026, against a year earlier
Follow TGTX
Alert me
TG Therapeutics, Inc. (TGTX) Revenue
TG Therapeutics, Inc.'s revenue for fiscal 2025 was $616.3M, up 87.3% from $329.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $799.5M. Over the past ten years it has ranged from $152.0K (fiscal 2020) to $616.3M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. TG Therapeutics, Inc. ranks 31st of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $616.3M | 87.32% |
| FY2024 | $329.0M | 40.80% |
| FY2023 | $233.7M | 8,290.02% |
| FY2022 | $2.8M | (58.36%) |
| FY2021 | $6.7M | 4,300.66% |
| FY2020 | $152.0K | 0.00% |
| FY2019 | $152.0K | 0.00% |
| FY2018 | $152.0K | 0.00% |
| FY2017 | $152.0K | 0.00% |
| FY2016 | $152.0K | (0.26%) |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Jun 2026 | $240.3M | 17.28% |
| Mar 2026 | $204.9M | 6.41% |
| Dec 2025 | $192.6M | 19.09% |
| Sep 2025 | $161.7M | 14.57% |
| 42 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| MDGL Madrigal Pharmaceuticals, Inc. compare | $1.4B |
| CAI Caris Life Sciences,�Inc. compare | $1.0B |
| TGTX TG Therapeutics, Inc. | $799.5M |
| KRYS Krystal Biotech, Inc. compare | $470.0M |
| TWST Twist Bioscience Corporation compare | $431.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $282.0M |
| IBRX ImmunityBio, Inc. compare | $165.8M |
| CYTK Cytokinetics, Incorporated compare | $113.3M |
| SYRE Spyre Therapeutics, Inc. compare | $1.1M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on TGTX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement